123 related articles for article (PubMed ID: 31337543)
1. High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores.
Morgan TM; Rossi PJ; Cutrell PK; Zhang C; Press RH; Rahnema S; Sanda M; Pattaras J; Cimmino C; Hershatter B; Jani AB; Patel PR
Brachytherapy; 2019; 18(6):793-799. PubMed ID: 31337543
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60 cc) and large (≥60 cc) prostate glands.
Press RH; Morgan TM; Cutrell PK; Zhang C; Chen Z; Rahnema S; Sanda M; Pattaras J; Patel P; Jani AB; Rossi PJ
Brachytherapy; 2019; 18(1):13-21. PubMed ID: 30262410
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Lief JH; Galbreath RW
Urology; 2002 Oct; 60(4):650-5. PubMed ID: 12385927
[TBL] [Abstract][Full Text] [Related]
4. Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boost.
Ben Aicha I; Hathout L; Carignan D; Després P; Lavallée MC; Aubin S; Beaulieu L; Lacroix F; Foster W; Martin AG; Vigneault E
Brachytherapy; 2020; 19(5):584-588. PubMed ID: 32928485
[TBL] [Abstract][Full Text] [Related]
5. Early toxicity and health-related quality of life results of high-dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer.
Gaudet M; Pharand-Charbonneau M; Desrosiers MP; Wright D; Haddad A
Brachytherapy; 2018; 17(3):524-529. PubMed ID: 29482918
[TBL] [Abstract][Full Text] [Related]
6. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
[TBL] [Abstract][Full Text] [Related]
7. A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer.
Lee WR; McQuellon RP; Harris-Henderson K; Case LD; McCullough DL
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):77-81. PubMed ID: 10656376
[TBL] [Abstract][Full Text] [Related]
8. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
9. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported Quality of Life After SBRT, LDR, and HDR Brachytherapy for Prostate Cancer: A Comparison of Outcomes.
Paly JJ; Egleston BL; Wong JK; Burbure N; Sobczak ML; Hayes SB; Chen DYT; Horwitz EM; Hallman MA
Am J Clin Oncol; 2021 Apr; 44(4):131-136. PubMed ID: 33577175
[TBL] [Abstract][Full Text] [Related]
11. Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy.
Farris JC; Hughes RT; Steber CR; Craven TE; Frizzell BA
Brachytherapy; 2021; 20(6):1107-1113. PubMed ID: 34353749
[TBL] [Abstract][Full Text] [Related]
12. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
13. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
14. Early quality of life outcomes in patients with prostate cancer managed by high-dose-rate brachytherapy as monotherapy.
Komiya A; Fujiuchi Y; Ito T; Morii A; Yasuda K; Watanabe A; Nozaki T; Iida H; Nomura K; Fuse H
Int J Urol; 2013 Feb; 20(2):185-92. PubMed ID: 22905941
[TBL] [Abstract][Full Text] [Related]
15. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy.
Morton G; Chung HT; McGuffin M; Helou J; D'Alimonte L; Ravi A; Cheung P; Szumacher E; Liu S; Al-Hanaqta M; Zhang L; Mamedov A; Loblaw A
Radiother Oncol; 2017 Jan; 122(1):87-92. PubMed ID: 27823821
[TBL] [Abstract][Full Text] [Related]
16. Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms.
Winoker JS; Say RK; Mehrazin R; Stock RG; Stone NN
Brachytherapy; 2019; 18(3):332-337. PubMed ID: 30890317
[TBL] [Abstract][Full Text] [Related]
17. The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Allen ZA; Lief JH; Hinerman-Mulroy A; Galbreath RW
Cancer J; 2004; 10(3):181-9. PubMed ID: 15285928
[TBL] [Abstract][Full Text] [Related]
18. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
[TBL] [Abstract][Full Text] [Related]
19. Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial.
Gomez-Iturriaga A; Casquero F; Pijoan JI; Minguez P; Espinosa JM; Irasarri A; Bueso A; Cacicedo J; Buchser D; Bilbao P
Radiother Oncol; 2018 Feb; 126(2):278-282. PubMed ID: 29153462
[TBL] [Abstract][Full Text] [Related]
20. Prediction of urinary symptoms after 125iodine prostate brachytherapy.
Kelly K; Swindell R; Routledge J; Burns M; Logue JP; Wylie JP
Clin Oncol (R Coll Radiol); 2006 May; 18(4):326-32. PubMed ID: 16703751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
